181 related articles for article (PubMed ID: 22285309)
21. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.
Legos JJ; Lenhard SC; Haimbach RE; Schaeffer TR; Bentley RG; McVey MJ; Chandra S; Irving EA; Andrew A Parsons ; Barone FC
Exp Neurol; 2008 Jul; 212(1):53-62. PubMed ID: 18462720
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.
Burgos E; Gómez-Nicola D; Pascual D; Martín MI; Nieto-Sampedro M; Goicoechea C
Eur J Pharmacol; 2012 May; 682(1-3):62-72. PubMed ID: 22374260
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotective Action of the CB1/2 Receptor Agonist, WIN 55,212-2, against DMSO but Not Phenobarbital-Induced Neurotoxicity in Immature Rats.
Huizenga MN; Forcelli PA
Neurotox Res; 2019 Jan; 35(1):173-182. PubMed ID: 30141144
[TBL] [Abstract][Full Text] [Related]
24. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia.
Muthian S; Rademacher DJ; Roelke CT; Gross GJ; Hillard CJ
Neuroscience; 2004; 129(3):743-50. PubMed ID: 15541895
[TBL] [Abstract][Full Text] [Related]
25. Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: therapeutic time window, combination with t-PA and efficacy in aged rats.
Murakami K; Suzuki M; Suzuki N; Hamajo K; Tsukamoto T; Shimojo M
Brain Res; 2013 Aug; 1526():84-93. PubMed ID: 23791950
[TBL] [Abstract][Full Text] [Related]
26. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
[TBL] [Abstract][Full Text] [Related]
27. The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion.
Chen J; Yu H; Zhong J; Feng H; Wang H; Cheng Y; Zou Z; Huang C; Zhou Z; Zheng W; Xu J
Brain Res Bull; 2018 Mar; 137():98-106. PubMed ID: 29155261
[TBL] [Abstract][Full Text] [Related]
28. Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates.
Suzuki N; Suzuki M; Murakami K; Hamajo K; Tsukamoto T; Shimojo M
Brain Res; 2012 Jan; 1430():93-100. PubMed ID: 22119394
[TBL] [Abstract][Full Text] [Related]
29. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
30. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury.
Zhang M; Martin BR; Adler MW; Razdan RK; Ganea D; Tuma RF
Neuroscience; 2008 Mar; 152(3):753-60. PubMed ID: 18304750
[TBL] [Abstract][Full Text] [Related]
31. A translocator protein 18 kDa agonist protects against cerebral ischemia/reperfusion injury.
Li HD; Li M; Shi E; Jin WN; Wood K; Gonzales R; Liu Q
J Neuroinflammation; 2017 Jul; 14(1):151. PubMed ID: 28754131
[TBL] [Abstract][Full Text] [Related]
32. Ceftriaxone pretreatment protects rats against cerebral ischemic injury by attenuating microglial activation-induced IL-1β expression.
Lujia Y; Xin L; Shiquan W; Yu C; Shuzhuo Z; Hong Z
Int J Neurosci; 2014 Sep; 124(9):657-65. PubMed ID: 24985046
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 ameliorate neuroinflammatory responses in chronic cerebral hypoperfusion model by blocking NF-κB pathways.
Su SH; Wu YF; Lin Q; Hai J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1189-1200. PubMed ID: 28825114
[TBL] [Abstract][Full Text] [Related]
34. Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia.
Bonfils PK; Reith J; Hasseldam H; Johansen FF
Neurochem Int; 2006 Oct; 49(5):508-18. PubMed ID: 16730099
[TBL] [Abstract][Full Text] [Related]
35. Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats.
Järbe TU; Ross T; DiPatrizio NV; Pandarinathan L; Makriyannis A
Pharmacol Biochem Behav; 2006 Sep; 85(1):243-52. PubMed ID: 16996123
[TBL] [Abstract][Full Text] [Related]
36. The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation.
Zhang Z; Qin P; Deng Y; Ma Z; Guo H; Guo H; Hou Y; Wang S; Zou W; Sun Y; Ma Y; Hou W
J Neuroinflammation; 2018 Jul; 15(1):206. PubMed ID: 30001721
[TBL] [Abstract][Full Text] [Related]
37. LXW7 ameliorates focal cerebral ischemia injury and attenuates inflammatory responses in activated microglia in rats.
Fang T; Zhou D; Lu L; Tong X; Wu J; Yi L
Braz J Med Biol Res; 2016 Aug; 49(9):e5287. PubMed ID: 27533766
[TBL] [Abstract][Full Text] [Related]
38. WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture.
Aguirre-Rueda D; Guerra-Ojeda S; Aldasoro M; Iradi A; Obrador E; Mauricio MD; Vila JM; Marchio P; Valles SL
PLoS One; 2015; 10(4):e0122843. PubMed ID: 25874692
[TBL] [Abstract][Full Text] [Related]
39. Repeated social defeat-induced neuroinflammation, anxiety-like behavior and resistance to fear extinction were attenuated by the cannabinoid receptor agonist WIN55,212-2.
Lisboa SF; Niraula A; Resstel LB; Guimaraes FS; Godbout JP; Sheridan JF
Neuropsychopharmacology; 2018 Aug; 43(9):1924-1933. PubMed ID: 29786066
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity.
Kim SH; Won SJ; Mao XO; Jin K; Greenberg DA
Mol Pharmacol; 2006 Mar; 69(3):691-6. PubMed ID: 16299067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
